NEW YORK (GenomeWeb) – Danaher said today that it plans to acquire Cepheid for nearly $4 billion in cash. The deal is expected to close by the end of the year.

Under the terms of the merger agreement, Danaher will acquire all of Cepheid's outstanding stock for $53.00 per share, a 54 percent premium to Friday's close. Including Cepheid's indebtedness, this represents a total enterprise value of approximately $4 billion. 

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Jan
30
Sponsored by
Loop Genomics

This webinar will provide a comparison of several next-generation sequencing (NGS) approaches — including short-read 16S, whole-genome sequencing (WGS), and synthetic long-read sequencing technology — for use in microbiome research studies.

Jan
30
Sponsored by
Loop Genomics

This webinar will provide a comparison of several next-generation sequencing (NGS) approaches — including short-read 16S, whole-genome sequencing (WGS), and synthetic long-read sequencing technology — for use in microbiome research studies.